Fortrea inks deal with Australia’s Incannex for sleep apnea drug trial
2023-07-27
临床3期临床2期
Preview
来源: FierceBiotech
Fresh off its spinoff from Labcorp, CRO Fortrea has signed a deal with Incannex Healthcare to manage clinical trials for a cannabinoid-based treatment for obstructive sleep apnea.
Fortrea has inked a deal with Australia’s Incannex Healthcare to manage investigative new drug (IND) clinical trials for a cannabinoid-based treatment for obstructive sleep apnea.
The phase 2 and phase 3 trials will be designed to assess Incannex’s IHL-42X, a low dose of the anti-nausea drug dronabinol, a synthetic form of tetrahydrocannabinol (THC), and the diuretic acetazolamide.
A fairly common condition, obstructive sleep apnea causes the walls of the throat to relax and narrow during sleep, interrupting normal breathing that can lead to regularly interrupted sleep. In more severe cases, the condition can temporarily stop breathing during sleep.
Fortrea—the CRO spinoff from Labcorp—was previously engaged in a 12-week operational feasibility study of the trial that was provided to potential investigators to gauge their interest, the company said in a July 18 press release. While 63 sites said they were interested, Incannex is targeting 45 for the study.
“Fortrea’s familiarity with the study and established relationships with potential trial sites will expedite the study start-up and site engagement activities,” Joel Latham, Incannex chief executive and managing director, said in the release.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。